Статья
КОТРАНСПОРТ НАТРИЯ, КАЛИЯ И ХЛОРА КАК РЕГУЛЯТОР СОСУДИСТОГО ТОНУСА: РОЛЬ В ПАТОГЕНЕЗЕ СИСТЕМНОЙ И ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ
В обзоре рассматриваются механизмы вовлечения универсальной изоформы переносчика, осуществляющего электронейтральный симпорт натрия, калия и хлора (Na+, K+, 2Cl–-котранспорт — NKCC1) в регуляцию сокращения гладких мышц сосудов большого и малого кругов кровообращения и патогенез эссенциальной и легочной гипертензии. Особое внимание уделено возможности использования NKCC1 как новой мишени для нормализации кровяного давления. В этой связи рассмотрены данные об ингибировании петлевыми диуретиками — селективными ингибиторами NKCC1 — миогенного ответа резистентных сосудов большого круга кровообращения и афферентной артериолы почки, а также о действии ингаляционных форм этих соединений на гладкомышечные клетки воздухопроводящих путей.
1. Adragna N, Di Fulvio M, Lauf PK. Regulation of K-Cl cotransport: from function to genes. J Membr Biol. 2004;201(3): 109–137. doi:10.1007/s00232–004–0695–6
2. Gamba G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol. 2005;85(2): 423–493. doi:10.1152/physrev.00011.2004
3. Orlov SN, Mongin AA. Salt sensing mechanisms in blood pressure regulation and hypertension. Am J Physiol Heart Circ Physiol. 2007;293: H2039-H2053. doi:10.1152/ ajpheart.00325.2007
4. Markadieu N, Delpire E. Physiology and pathophysiology of SLC12A1/2 transporters. Pfluger Arch Eur J Physiol. 2014;466(1): 91–105. doi:10.1007/s00424–013–1370–5
5. Орлов С. Н., Кольцова С. В., Капилевич Л. В., Дулин Н. О., Гусакова С. В. Котранспортеры катионов и хлора: регуляция, физиологическое значение и роль в патогенезе артериальной гипертензии. Успехи биологической химии. 2014;54:267–298..
6. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrinology. 2001;22:153–183. doi:10.1210/edrv.22.2.0428
7. Orlov SN, Tremblay J, Hamet P. NKCC1 and hypertension: a novel therapeutic target involved in regulation of vascular tone and renal function. Curr Opin Nephrol Hypert. 2010;19:163–168. doi:10.1097/MNH.0b013e3283360a46
8. Orlov SN, Koltsova SV, Tremblay J, Baskakov MB, Hamet P. NKCC1 and hypertension: role in the regulation of vascular smooth muscle contractions and myogenic tone. Ann Med. 2012;44: S111-S118. doi:10.3109/07853890.2011.653395
9. Orlov SN. NKCC1 as an epigenetically regulated transporter involved in blood pressure elevation with age. Am J Hypertens. 2011;24:1264. doi:10.1038/ajh.2011.150
10. Orlov SN, Koltsova SV, Kapilevich LV, Gusakova SV, Dulin NO. NKCC1 and NKCC2: The pathogenetic role of cationchloride cotransporters in hypertension. Gens Dis. 2015;2:186–196. doi:10.1016/j.gendis.2015.02.007
11. Reho JJ, Zheng X, Fisher SA. Smooth muscle contractile diversity in the control of regional circulations. Am J Physiol Heart Circ Physiol. 2014;306(2): H163-H172. doi:10. 1152/ajpheart.00493.2013
12. Chipperfield AR, Harper AA. Chloride in smooth muscle. Prog Biophys Mol Biol. 2001;74(3–5):175–221.
13. Bulley S, Jaggar JH. Cl- channels in smooth muscle cells. Pfluger Arch Eur J Physiol. 2014;466(5):861–872.
14. Matchkov VV, Boedtkier DM, Aalkjaer C. The role of Ca2+ activated Cl- channels in blood pressure control. Curr Opin Pharmacol. 2015;21:127–137. doi:10.1016/j.coph.2015.02.003
15. Leblanc N, Forrest AS, Ayon RJ, Wiwchar M, Angermann JE, Pritchard HAT et al. Molecular and functional significance of Ca2+-activated Cl- channels in pulmonary arterial hyperetnsion. Pulm Circ. 2015;5(2):244–268. doi:10.1086/680189
16. Forrest AS, Joyce TC, Huebner ML, Ayon RJ, Wiwchar M, Joyce C et al. Increased TMEM16A-enoded calcium-activated chloride channel activity is associated with pulmonary hypertension. Am J Physiol Cell Physiol. 2012;303(12): C1229-C1243. doi:10.1152/ajpcell.00044.2012
17. Sun H, Xia Y, Paudel O, Yang XR, Sham JS. Chronic hypoxia-induced upregulation of Ca2+-activated Cl- channels in pulmonaty artery myocytes: a mechanism contributing to enhanced vasoreactivity. J Physiol. 2012;590(15):3507–3521. doi:10.1113/jphysiol.2012.232520
18. Heinze C, Seniuk A, Sokolov MV, Huebner AK, Klementowicz AE, Szijarto IA et al. Disruption of vascular Ca2+activated chloride currents lowers blood pressure. J Clin Invest. 2014;124(2):675–686. doi:10.1172/JCI70025
19. Kaplan MR, Plotkin MD, Brown D, Hebert SC, Delpire E. Expression of the mouse Na-K-2Cl cotransporter, mBSC2, in the terminal inner medullary collecting duct, the glomerular and extraglomerular mesangium, and glomerular afferent arteriole. J Clin Invest. 1996;98(3):723–730. doi:10.1172/JCI118844
20. Hubner CA, Lorke DE, Hermans-Borgmeyer I. Expression of the Na-K-2Cl-cotransporter NKCC1 during mouse development. Mech Dev. 2001;102(1–2):267–269.
21. Rust MB, Faulhaber J, Budack M, Pfeffer C, Maritzen T, Didie M et al. Neurogenic mechanisms contribute to hypertension in mice with disruption of the C–Vl-cotransporter KCC3. Circ Res. 2006;98(4):549–556. doi:10.1161/01.RES.0000204449.83861.22
22. Boedtkier E, Aalkjaer C. Intracellular pH in the resistance vasculature: regulation and functional implications. J Vasc Res. 2012;49(6):479–496. doi:10.1159/000341235
23. Brosius FC, Pisoni RL, Cao X, Deshmukh G, Yannoukakos D, Stuart-Tilley AK et al. AE anion exchager mRNA and protein expression in vascular smooth muscle cells, aorta and renal microvessels. Am J Physiol. 1997;273(6 Pt 2): F1039-F1047.
24. Davis JPL, Chipperfield AR, Harper AA. Accumulation of intracellular chloride by (Na-K-Cl) cotransport in rat arterial smooth muscle is enhanced in deoxycorticosterone acetate (DOCA)/salt hypertension. J Mol Cell Cardiol. 1993;25(3): 233–237.
25. Anfinogenova YJ, Baskakov MB, Kovalev IV, Kilin AA, Dulin NO, Orlov SN. Cell-volume-dependent vascular smooth muscle contraction: role of Na+, K+, 2Cl- cotransport, intracellular Cl- and L-type Ca2+ channels. Pflugers Arch. Eur J Physiol. 2004;449:42–55. doi:10.1007/s00424–004–1316-z
26. Hubner CA, Schroeder BC, Ehmke H. Regulation of vascular tone and arterial blood pressure: role of chloride transport in vascular smooth muscle. Pflugers Arch. Eur J Physiol. 2015;467(3):605–614. doi:10.1007/s00424–014–1684-y
27. (5) / 2017 371 23(5) / 2017
28. Barthelmebs M, Stephan D, Fontaine C, Grima M, Imbs JL. Vascular effects of loop diuretics: an in vivo and in vitro study in the rat. Naunyn-Schmiedebergs Arch Pharmacol. 1994;349 (2):209–216.
29. Lavallee SL, Iwamoto LM, Claybaugh JR, Dressel MV, Sato AK, Nakamura KT. Furosemide-induced airway relaxation in guinea pigs: relation to Na-K-2Cl cotransporet function. Am J Physiol. 1997;273 (1 Pt 1): L211-L216.
30. Tian R, Aalkjaer C, Andreasen F. Mechanisms behind the relaxing effect of furosemide on the isolated rabbit ear artery. Pharmacol Toxicol. 1990;67(5):406–410.
31. Kovalev IV, Baskakov MB, Anfinogenova YJ, Borodin YL, Kilin AA, Minochenko IL et al. Effect of Na+, K+, 2Cl- cotransport inhibitor bumetanide on electrical and contractile activity of smooth muscle cells in guinea pig ureter. Bull Exp Biol Med. 2003;136(8):145–149.
32. Ковалев И. В., Баскаков М. Б., Медведев М. А., Миноченко И. Л., Килин А. А., Анфиногенова Я. Д. и др.. Изучение роли Na+, K+, 2Cl-котранспорта и хлорной проводимости мембраны в регуляции электрической и сократительной активности гладкомышечных клеток мочеточника морской свинки мезатономигистамином. Российский физиологический журнал им. И. М. Сеченова. 2007;93:306–317.
33. Stanke F, Devillier P, Breant D, Chavanon O, Sessa C, Bricca G et al. Furosemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Br J Clin Pharmacol. 1998;46(6):571–575.
34. Stanke-Labesque F, Craciwski JL, Bedouch P, Chavanon O, Magne JL, Bessard G et al. Furosemide inhibits thrombaxane A2-induced contraction in isolated human internal artery and saphenous vein. J Cardiovasc Pharmacol. 2000;35(4):531–537.
35. Wang X, Breaks J, Loutzenhiser K, Loutzenhiser R. Effects of inhibition of the Na+/K+/2Cl- cotransporter on myogenic and angiotensin II responses of the rat afferent arteriole. Am J Physiol Renal Physiol. 2007;292(3): F999-F1006. doi:10. 1152/ajprenal.00343.2006
36. Mozhayeva MG, Bagrov YY. The inhibitory effects of furosemide on Ca2+ influx pathways associated with oxytocininduced contractions of rat myometrium. Gen Physiol Biophys. 1995;14(5):427–436. 36. Mozhayeva MG, Bagrov YY, Ostretsova IB, Gillespie JI. The effect of furosemide on oxytocin-induced contractions of the rat myometrium. Exp Physiol. 1994;79(5):661–667.
37. Akar F, Skinner E, Klein JD, Jena M, Paul RJ, O'Neill WC. Vasoconstrictors and nitrovasodilators reciprocally regulate the Na+-K+-2Cl- cotransporter in rat aorta. Am J Physiol. 1999;276 (6 Pt 1): C1383-C1390.
38. Garg P, Martin C, Elms SC, Gordon FJ, Wall SM, Garland CJ et al. Effect of the Na-K-2Cl cotransporter NKCC1 on systematic blood pressure and smooth muscle tone. Am J Physiol Heart Circ Physiol. 2007;29(5): H2100-H2105. doi:10. 1152/ajpheart.01402.2006
39. Palacios J, Espinoza F, Munita C, Cifuentes F, Michea L. Na+-K+-2Cl- cotransporter is implicated in gender differences in the response of the rat aorta to phenylephrine. Br J Pharmacol. 2006;148(7):964–972. doi:10.1038/sj.bjp.0706818
40. Koltsova SV, Maximov GV, Kotelevtsev SV, Lavoie JL, Tremblay J, Grygorczyk R, Hamet P, Orlov SN. Myogenic tome in mouse mesenteric arteries: evidence for P2Y receptor-mediated, Na+, K+, 2Cl-cotransport-dependent signaling. Purinergic Signaling. 2009;5:343–349.
41. Valero M, Pereboom D, Garay RP, Alda JO. Role of chloride transport proteins in the vasorelaxant action of nitroprusside in isolated rat aorta. Eur J Pharmacol. 2006;553 (1–3):205–208. doi:10.1016/j.ejphar.2006.09.015
42. Koltsova SV, Kotelevtsev SV, Tremblay J, Hamet P, Orlov SN. Excitation-contraction coupling in resistant mesenteric arteries: evidence for NKCC1-mediated pathway. Biochem.Biophys.Res. Commun. 2009;379:1080–1083.
43. Dayioglu E, Buharalioglu K, Saracoglu F, Akar F. The effects of bumetanide on human umbilical artery contractions. Reproductive Sci. 2007;14(3):246–252. doi:10.1177/1933719107300871
44. Koltsova SV, Luneva OG, Lavoie JL, Tremblay J, Maksimov GV, Hamet P, Orlov SN. HCO3-dependent impact of Na+, K+,2Cl- cotransport in vascular smooth muscle excitationcontraction coupling. Cell.Physiol.Biochem. 2009;23:407–414. doi:10.1159/000218187
45. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79(2):387–423.
46. Hill MA, Davis MJ, Meininger GA, Potocnik SJ, Murphy TV. Arteriolar myogenic signaling mechanisms: implications for local vascular functions. Clin Hemorheol Microcirc. 2006;34 (1–2):67–79.
47. Schubert R, Mulvany MJ. The myogenic response: established facts and attractive hypothesis. Clin Sci. 1999;96 (4):313–326.
48. Oriowo MA. Chloride channels and a1-adrenoceptormediated pulmonary artery smooth muscle contraction: effect of pulmonary hypertension. Eur J Pharmacol. 2004;506(2):157–163.
49. Greenberg S, McGowan C, Xie J, Summer WR. Selective pulmonary and venous smooth muscle relaxation by furosemide: a comparison with morphine. J Pharmacol Exp Ther. 1994;270(3): 1077–1085.
50. Cotton R, Suarez S, Reese J. Unexpected extra-renal effects of loop diuretics in the preterm neonate. Acta Pediatrica. 2012;101(8): 835–845. doi:10.1111/j.1651–2227.2012.02699.x
51. Postnov YuV, Orlov SN. Ion transport across plasma membrane in primary hypertension. Physiol Rev. 1985;65:904–945
52. Orlov SN, Adragna N, Adarichev VA, Hamet P. Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. Am J Physiol. 1999;276: C511-C536
53. Garay RP, Alda O. What can we learn from erythrocyte NaK-Cl cotransporter NKCC1 in human hypertension? Pathophysiology. 2007;14(3–4):167–170. doi:10.1016/j.pathophys.2007.09.006
54. Korpi ER, Luddens H. Furosemide interactions with brain GABAA receptors. Br J Pharmacol. 1997;120(5):741–748.
55. Lee HA, Baek I, Seok YM, Yang E, Cho HM, Lee DY et al. Promoter hypomethylation upregulates Na+-K+-2Cl- cotransporter 1 in spontaneously hypertensive rats. Biochem Biophys Res Commun. 2010;396(2):252–257. doi:10.1016/j.bbrc.2010.04.074
56. Ye ZY, Li DP, Byun HS, Li L, Pan HL. NKCC1 upregulation disrupts chloride homeostasis in the hypothalamus and increases neuronal-sympathetic drive in hypertension. J Neurosci. 2012;32(25): 8560–8568. doi:10.1523/JNEUROSCI.1346–12.2012
57. Cho HM, Lee HA, Kim HY, Han HS, Kim IK. Expression of Na+, K+-2Cl- cotransporter is epigenetically regulated during postnatal development of hypertension. Am J Hypertens. 2011;24(12): 1286–1293. doi:10.1038/ajh.2011.136
58. Brown RA, Chipperfield AR, Davis JPL, Harper AA. Increased (Na+K+Cl-) cotransport in rat arterial smooth muscle in deoxycorticosterone (DOCA)/salt-induced hypertension. J Vasc Res. 1999;36(6):492–501.
59. Jiang G, Akar F, Cobbs SL, Lomashvilli K, Lakkis R, Gordon FJ et al. Blood pressure regulates the activity and function of Na-K-2Cl cotransporter in vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2004;286(4): H1552-H1557. doi:10.1152/ajpheart.00695.2003
60. Jiang G, Cobbs S, Klein JD, O'Neill WC. Aldosterone regulates the Na-K-2Cl cotransporter in vascular smooth muscle. Hypertension. 2003;41(5):1131–1135. doi:10.1161/01.HYP. 0000066128.04083.CA
61. Ding B, Frisina RD, Zhu X, Sakai Y, Sokolowski B, Walton JP. Direct control of Na+-K+-2Cl- cotransport protein (NKCC1) expression with aldosterone. Am J Physiol Cell Physiol. 2014;306(1): C66-C75. doi:10.1152/ajpcell.00096.2013
62. Cho HM, Lee DY, Kim HY, Lee HA, Seok YM, Kim IK. Upregulation of the Na+-K+-2Cl- cotransporter 1 via histone modification in the aortas of angiotensin IIinduced hypertensive rats. Hypertens.Res. 2012;35(8):819–824. doi:10.1038/hr.2012.37
63. Orlov SN. Decreased Na+, K+, Cl-cotransport and salt retention in Blacks: a provocative hypothesis. J. Hypertens. 2005;23:1929–1930.
64. Boone CA. End-stage renal disease in African-Americans. Nephrol Nurs J. 2000;27(6):597–600.
65. Orlov SN, Gossard F, Pausova Z, Akimova OA, Tremblay J, Grim CE et al. Decreased NKCC1 activity in erythrocytes from African-Americans with hypertension and dyslipidemia. Am J Hypertens. 2010;23:321–326. doi:10.1038/ajh.2009.249
66. Huber LC, Bye H, Brock M. The pathogenesis of pulmonary hypertension — an update. Swiss Medical Weekly. 2015;145: w14202. doi:10.4414/smw.2015.14202
67. Kanwar MK, Thenappan T, Vachiery JL. Update in treatment options in pulmonary hypertension. J Heart Lung Transplant. 2016;35(6):695–703. doi:10.1016/j.healun.2016.01.020
68. Noordegraaf AV, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. Eur Respir Rev. 2016;25(139):4–11. doi:10.1183/16000617.0096–2015
69. Cuttica MJ. Pulmonary hypertension associated with lung diseases and hypoxemia. Heart Fail Rev. 2016;21(3):299–308. doi:10.1007/s10741–016–9551-x
70. Hambly N, Alawfi F, Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016;188 (11):804–12. doi:10.1503/cmaj.151075
71. Velayti A, Valerio MG, Shen D, Tariq S, Lanier GM, Aronow WS. Update on pulmonary arterial hypertension pharmacotherapy. Postgraduate Medicine. 2016;128(5):460–473. doi:10.1080/00325481.2016.1188664
72. Hu J, Xu Q, McTiernan C, Lai YC, Osei-Hwedieh D, Gladwin M. Novel targets of drug treatment for pulmonary hypertension. Am J Cardiovasc Drugs. 2015;15(4):225–234. doi:10.1007/s40256–015–0125–4
73. Humbert M, Ghofrani HS. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71(1):73–83. doi:10.1136/thoraxjnl-2015–207170
74. Bianco S, Robuschi M, Vaghi A, Fumagall A, Sestini P. Inhaled transmembrane ion transport modulators and non-steroidal anti-inflammatory drugs in asthma. Thorax. 2000;55 (suppl 2): S48-S50.
75. Inokuchi R, Aoki A, Aoki Y, Yahagi N. Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis. Crit Care. 2014;18(6):621. doi:10.1186/s13054–014–0621-y
76. Spicuzza L, Ciancio N, Pellegrino R, Bellofiore S, Polosa R, Ricciardolo FL et al. The effect of inhaled furosemide and acetazolamide on broncoconstriction induced by deep inspiration in asthma. Monaldi Arch Chest Dis. 2003;59(2):150–154.
77. Cavaliere F, Masieri S. Furosemide protective effect against airway obstruction. Curr Drug Targets. 2002;3(3):197–201.
78. Masoumi K, Forouzan A, Shoushtari MH, Porozan S, Feli M, Sheidaee MFB et al. The efficacy of neubulized furosemide and salbutamol compared with salbutamol alone in reactive airway: a double blind randomized, clinical trial. Emerg Med Int. 2014;2014:638102. doi:10.1155/2014/638102
79. Bialasiewicz P, Wlodarczyk A, Dudkiewicz B, Nowak D. Inhibitory effect of furosemide on activation of human peripheral blood plymorphonuclear leukocytes stimulated with n-gormyl-methionyl-leucyl-phenylalanine. Int.Immunopharmacol. 2004;4(6):819–831. doi:10.1016/j.intimp.2004.01.024
80. Iwamoto LM, Fujiwara N, Nakamura KT, Wada RK. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am. J. Physiol.Lung Cell Mol Physiol. 2004;287(3): L510-L514. doi: 10.1152/ajplung.00021.2004
81. Salvi SS. a1-Adrenergic hypothesis for pulmonary hypertension. Chest. 1999;115(6):1708–1719.
82. Molimard M, Naline E, Hirsch A, Advenier C. Furosemide inhibits bradykinin-induced contraction of human brochi: role of thromboxane A2 receptor antagonism. Eur J Pharmacol. 1995;278(3):253–256.
83. Meyer JW, Flagella M, Sutliff RL, Lorenz JN, Nieman ML, Weber GS, et al. Decreased blood pressure and vascular smooth muscle tone in mice lacking basolateral Na+-K+2Cl- cotransporter. Am J Physiol. 2002;283(5): H1846-H1855. doi:10.1152/ajpheart.00083.2002
84. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno A, Zalba G et al. Torasemide inhibits angiotensin IIinduced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34(1): 138–143.
85. Shen B, Fu J, Guo J, Zhang J, Wang X, Pan X et al. Role of Na+-K+-2Cl- cotransporter 1 in phenylephrine-induced rhytmic contraction in the mouse aorta: regulation of Na+-K+-2Cl- cotransporter 1 by Ca2+ sparks and KCa channels. Cell Physiol Biochem. 2015;37(2):747–758. doi: 10.1159/000430392